# US 2019/0376034 A1 · Platelets comprising exogenous polypeptides and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0376034 A1
- Document ID: US20190376034A1
- Status: Published application
- Kind: A1
- Application number: 16/549,840
- Filed: 2019-08-23
- Published: 2019-12-12
- Earliest claimed: 2013-11-18
- Assignees: Rubius Therapeutics, Inc.
- Applicants: Rubius Therapeutics, Inc.
- Inventors: Avak Kahvejian; Jordi Mata-Fink; John Round; David Arthur Berry; Noubar B. Afeyan
- Web page: https://patentgrep.com/patent/US20190376034A1

## CPC

- C12N 5/0641: {Erythrocytes}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/5068: {Cell membranes or bacterial membranes enclosing drugs (liposomes with additional exogenous lipids A61K9/127)}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 35/18: Erythrocytes (haemoglobin A61K38/42)
- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61K 38/1774: {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
- A61K 39/001: {Preparations to induce tolerance to non-self, e.g. prior to transplantation}
- A61K 39/385: Haptens or antigens, bound to carriers
- A61K 47/6901: {Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/06: Antianaemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/082: Hepadnaviridae (F), e.g. hepatitis B virus
- C12N 9/88: Lyases (4.)
- C07K 2317/622: Single chain antibody (scFv)
- C12N 2510/00: Genetically modified cells
- C12Y 204/02004: Thymidine phosphorylase (2.4.2.4)
- C12Y 304/22: Cysteine endopeptidases (3.4.22)
- C12Y 403/01024: Phenylalanine ammonia-lyase (4.3.1.24)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.

## Claims

### Claim 1

A platelet comprising an exogenous polypeptide.

### Claim 2 (depends on 1)

The platelet of claim 1, which was produced by a process comprising introducing into the platelet an exogenous nucleic acid encoding the exogenous polypeptide.

### Claim 3 (depends on 1)

The platelet of claim 1, which was produced by a process comprising introducing into a nucleated platelet precursor cell an exogenous nucleic acid encoding the exogenous polypeptide.

### Claim 4 (depends on 1)

The platelet of claim 1, wherein the nucleated platelet precursor cell is a megakaryocyte, a hematopoietic stem cell, an induced pluripotent stem cell, or an embryonic stem cell.

### Claim 5 (depends on 1)

The platelet of claim 1, which was produced by introducing the exogenous polypeptide into the platelet by subjecting the platelet to a controlled cell injury.

### Claim 6 (depends on 5)

The platelet of claim 5, wherein the controlled cell injury caused a perturbation in the cell membrane of the platelet.

### Claim 7 (depends on 5)

The platelet of claim 5, wherein the controlled cell injury comprises cell deformation, electroporation, sonoporation, liposomal transfection, or salt-based transfection.

### Claim 8 (depends on 5)

The platelet of claim 5, wherein the controlled cell injury comprises cell deformation.

### Claim 9 (depends on 5)

The platelet of claim 5, wherein the controlled cell injury comprises cell squeezing.

### Claim 10 (depends on 2)

The platelet of claim 2, which was produced by introducing the exogenous nucleic acid into the platelet by subjecting the platelet to a controlled cell injury.

### Claim 11 (depends on 10)

The platelet of claim 10, wherein the controlled cell injury caused a perturbation in the cell membrane of the platelet.

### Claim 12 (depends on 10)

The platelet of claim 10, wherein the controlled cell injury comprises cell deformation, electroporation, sonoporation, liposomal transfection, or salt-based transfection.

### Claim 13 (depends on 10)

The platelet of claim 10, wherein the controlled cell injury comprises cell deformation.

### Claim 14 (depends on 10)

The platelet of claim 10, wherein the controlled cell injury comprises cell squeezing.

### Claim 15 (depends on 3)

The platelet of claim 3, which was produced by introducing the exogenous nucleic acid into the nucleated platelet precursor cell by subjecting the platelet to a controlled cell injury.

### Claim 16 (depends on 15)

The platelet of claim 15, wherein the controlled cell injury caused a perturbation in the cell membrane of the nucleated platelet precursor cell.

### Claim 17 (depends on 15)

The platelet of claim 15, wherein the controlled cell injury comprises cell deformation, electroporation, sonoporation, liposomal transfection, or salt-based transfection.

### Claim 18 (depends on 3)

The platelet of claim 3, which was produced by introducing the exogenous nucleic acid into the nucleated platelet precursor cell using viral transduction.

### Claim 19 (depends on 15)

The platelet of claim 15, wherein the controlled cell injury comprises cell squeezing.

### Claim 20 (depends on 3)

The platelet of claim 3, wherein the exogenous nucleic acid comprises DNA.

### Claim 21 (depends on 3)

The platelet of claim 3, wherein the exogenous nucleic acid comprises RNA.

### Claim 22 (depends on 1)

The platelet of claim 1, wherein the exogenous polypeptide comprises an enzyme, a cytokine, an antibody, a hormone, a receptor, or a functional fragment thereof.

### Claim 23 (depends on 1)

The platelet of claim 1, wherein the exogenous polypeptide is intracellular.

### Claim 24 (depends on 1)

The platelet of claim 1, wherein the exogenous polypeptide is at the surface of the platelet.

### Claim 25 (depends on 1)

The platelet of claim 1, wherein the exogenous polypeptide comprises a transmembrane domain.

### Claim 26 (depends on 1)

The platelet of claim 1, which comprises at least 1,000 copies of the exogenous polypeptide.

### Claim 27 (depends on 1)

The platelet of claim 1, which is a human cell.

### Claim 28 (depends on 1)

A pharmaceutical composition comprising the platelet of claim 1 and a pharmaceutically acceptable carrier.

### Claim 29 (depends on 1)

A method of producing the platelet of claim 1, comprising:
introducing into a nucleated platelet precursor cell an exogenous nucleic acid encoding the exogenous polypeptide; and
culturing the nucleated platelet precursor cell to produce the platelet.

### Claim 30 (depends on 1)

A method of producing the platelet of claim 1, comprising introducing into a platelet an RNA molecule encoding the exogenous polypeptide.

### Claim 31 (depends on 1)

A method of producing the platelet of claim 1, comprising introducing the exogenous polypeptide into a platelet by subjecting the platelet to a controlled cell injury.

### Claim 32 (depends on 31)

The method of claim 31, wherein the controlled cell injury caused a perturbation in the cell membrane of the platelet.

### Claim 33 (depends on 31)

The method of claim 31, wherein the controlled cell injury comprises cell deformation, electroporation, sonoporation, liposomal transfection, or salt-based transfection.

### Claim 34 (depends on 31)

The method of claim 31, wherein the controlled cell injury comprises cell deformation.

### Claim 35 (depends on 31)

The method of claim 31, wherein the controlled cell injury comprises cell squeezing.

### Claim 36 (depends on 1)

A method of treating a disease in a subject in need thereof, the method comprising administering to the subject the platelet of claim 1.

### Claim 37 (depends on 36)

The method of claim 36, wherein the disease comprises a metabolic disease, a cancer, a clotting disease, or an anti-clotting disease.
